caa a22 4500 445335734 CHVBK 20180317142754.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1665-8 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1665-8 Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer [Elektronische Daten] [Michael Meyers, Nancy Klauber-DeMore, David Ollila, Keith Amos, Dominic Moore, Amy Drobish, Emily Burrows, E. Dees, Lisa Carey] Background: Gene expression studies have identified distinct breast cancer subtypes, including luminal A, luminal B, Her2-enriched, and Basal-like, which differ in survival. The impact of subtypes on locoregional recurrence (LRR) after neoadjuvant chemotherapy for locally advanced breast cancer is unknown. Methods: A total of 149 patients with stage II and III breast cancer with known ER, PR, and HER2 who underwent neoadjuvant chemotherapy from 1991 to 2005 were analyzed. We used clinical assays to distinguish luminal A (ER or PR+/HER2−, n=55), luminal B (ER or PR+/HER2+, n=25), HER2 (ER and PR−/HER2+, n=20), and Basal-like (ER, PR, and HER2−, n=49) subtypes. Covariates associated with LRR were evaluated by logistic regression and differences between subtypes tested using Wald χ2. Results: Median follow-up was 55months. Forty-nine (33%) patients had breast conservation (BCT) with radiation, 82 (55%) had a mastectomy with radiation, and 18 (12%) had a mastectomy alone. Eighty-eight (59%) were clinically node positive. A pathologic complete response was seen in 39 (26%) patients. LRR was identified in 11 (7%) patients: 2 after BCT (4%) and 9 after mastectomy (9%). LRR rates by subtype are as follows: luminal A 2 of 55 (4%), luminal B 1 of 25 (4%), Her2 1 of 20 (5%), and basal-like 7 of 49 (14%). Compared with all other subtypes, basal-like patients were more likely to have a LRR (7/49 (14%) vs. 4/100 (4%), p=0.03). Conclusions: Molecular subtype predicts LRR with basal-like patients more likely to develop LRR. These patients may be candidates for investigation with novel chemotherapy regimens and radiation sensitizing agents, which may offer improvement in local control. Society of Surgical Oncology, 2011 Meyers Michael Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Klauber-DeMore Nancy Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Ollila David Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Amos Keith Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Moore Dominic The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Drobish Amy The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Burrows Emily The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Dees E. Division of Medical Oncology, Department of Medicine, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Carey Lisa Division of Medical Oncology, Department of Medicine, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2851-2857 1068-9265 18:10<2851 2011 18 10434 https://doi.org/10.1245/s10434-011-1665-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1665-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Meyers Michael Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Klauber-DeMore Nancy Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Ollila David Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Amos Keith Division of Surgical Oncology, Department of Surgery, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Moore Dominic The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Drobish Amy The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Burrows Emily The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Dees E. Division of Medical Oncology, Department of Medicine, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 700 1- Carey Lisa Division of Medical Oncology, Department of Medicine, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2851-2857 1068-9265 18:10<2851 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer